{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:26:36Z","timestamp":1790868396353,"version":"4.1.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13402-025-01054-9","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T06:50:49Z","timestamp":1743749449000},"page":"841-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors"],"prefix":"10.1007","volume":"48","author":[{"given":"Yanan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"2","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"D.G. Evans","year":"2010","unstructured":"D.G. Evans, E. Howard, C. Giblin, T. Clancy, H. Spencer, S.M. Huson, F. Lalloo, Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. GenetA. 152A(2), 327\u2013332 (2010). https:\/\/doi.org\/10.1002\/ajmg.a.33139","journal-title":"Am. J. Med. Genet"},{"issue":"1","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M. Lammert","year":"2005","unstructured":"M. Lammert, J.M. Friedman, L. Kluwe, V.F. Mautner, Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch. Dermatol. 141(1), 71\u201374 (2005). https:\/\/doi.org\/10.1001\/archderm.141.1.71.","journal-title":"Arch. Dermatol."},{"issue":"1","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","volume":"151","author":"S.A. Rasmussen","year":"2000","unstructured":"S.A. Rasmussen, J.M. Friedman, NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 151(1), 33\u201340 (2000). https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a010118","journal-title":"Am. J. Epidemiol"},{"issue":"3","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1590\/abd1806-4841.20132125","volume":"88","author":"J.R. Antonio","year":"2013","unstructured":"J.R. Antonio, E.M. Goloni-Bertollo, L.A. Tridico, Neurofibromatosis: chronological history and current issues. An Bras. Dermatol. 88(3), 329\u2013343 (2013). https:\/\/doi.org\/10.1590\/abd1806-4841.20132125","journal-title":"An Bras. Dermatol"},{"key":"1054_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2019.01.002","volume":"149","author":"S.F. Alves Junior","year":"2019","unstructured":"S.F. Alves Junior, G. Zanetti, A.S. Alves de Melo, A.S. Souza Jr, L.S. Souza, G. de Souza Portes Meirelles, K.L. Irion, B. Hochhegger, E. Marchiori, Neurofibromatosis type 1: state-of-the-art review with emphasis on pulmonary involvement. Respir. Med. 149, 9\u201315 (2019). https:\/\/doi.org\/10.1016\/j.rmed.2019.01.002","journal-title":"Respir. Med."},{"key":"1054_CR6","doi-asserted-by":"publisher","unstructured":"V. Reinhold, R.A. Kallionpaa, M. Valtanen, K. Auranen, S. Syrjanen, S. Peltonen, J. Peltonen, Hospital visits associated with oral infections in patients with neurofibromatosis Type 1: a register-based analysis. Am J. Med. Genet. A. e63887 (2024). https:\/\/doi.org\/10.1002\/ajmg.a.63887","DOI":"10.1002\/ajmg.a.63887"},{"issue":"6","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/1097-4547(20001215)62:6<755::AID-JNR1>3.0.CO;2-W","volume":"62","author":"M.M. Lakkis","year":"2000","unstructured":"M.M. Lakkis, G.I. Tennekoon, Neurofibromatosis type 1. I. General overview. J. Neurosci. Res. 62(6), 755\u2013763 (2000). https:\/\/doi.org\/10.1002\/1097-4547(20001215)62:6%3C;755::AID-JNR1%3E;3.0.CO;2-W","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","volume":"4","author":"J.P. Landry","year":"2021","unstructured":"J.P. Landry, K.L. Schertz, Y.J. Chiang, A.D. Bhalla, M. Yi, E.Z. Keung, C.P. Scally, B.W. Feig, K.K. Hunt, C.L. Roland, A. Guadagnolo, A.J. Bishop, A.J. Lazar, J.M. Slopis, I.E. McCutcheon, K.E. Torres, Comparison of cancer prevalence in patients with neurofibromatosis Type 1 at an academic cancer center vs in the general population From 1985 to 2020. JAMA Network Open. 4(3), e210945 (2021). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0945","journal-title":"JAMA Network Open"},{"issue":"5","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N. Ratner","year":"2015","unstructured":"N. Ratner, S.J. Miller, A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer. 15(5), 290\u2013301 (2015). https:\/\/doi.org\/10.1038\/nrc3911","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-24-1611","volume":"30","author":"M.R. Perrino","year":"2024","unstructured":"M.R. Perrino, A. Das, S.R. Scollon, S.G. Mitchell, M.C. Greer, M.E. Yohe, J.R. Hansford, J.M. Kalish, K.A.P. Schultz, S.P. MacFarland, W.K. Kohlmann, P.J. Lupo, K.N. Maxwell, S.M. Pfister, R. Weksberg, O. Michaeli, M.C.J. Jongmans, G.E. Tomlinson, J. Brzezinski, U. Tabori, G.M. Ney, K.W. Gripp, A.M. Gross, B.C. Widemann, D.R. Stewart, E.R. Woodward, C.P. Kratz, Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies. Clin. Cancer. Res. 30(21), 4834\u20134843 (2024). https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1611","journal-title":"Clin. Cancer. Res."},{"issue":"1","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/excr.2000.5138","volume":"264","author":"Y. Zhu","year":"2001","unstructured":"Y. Zhu, L.F. Parada, Neurofibromin, a tumor suppressor in the nervous system. Exp. Cell Res. 264(1), 19\u201328 (2001). https:\/\/doi.org\/10.1006\/excr.2000.5138","journal-title":"Exp. Cell Res"},{"key":"1054_CR12","doi-asserted-by":"publisher","unstructured":"D.K. Simanshu, D.V. Nissley, F. McCormick, RAS proteins and their regulators in human disease. Cell. 170(1), 17\u201333 (2017). https:\/\/doi.org\/10.1016\/j.cell.2017.06.009","DOI":"10.1016\/j.cell.2017.06.009"},{"issue":"6371","key":"1054_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/356713a0","volume":"356","author":"T.N. Basu","year":"1992","unstructured":"T.N. Basu, D.H. Gutmann, J.A. Fletcher, T.W. Glover, F.S. Collins, J. Downward, Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 356(6371), 713\u2013715 (1992). https:\/\/doi.org\/10.1038\/356713a0","journal-title":"Nature"},{"issue":"12","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41416-018-0073-2","volume":"118","author":"R.J. Allaway","year":"2018","unstructured":"R.J. Allaway, S.J.C. Gosline, S. La Rosa, P. Knight, A. Bakker, J. Guinney, L.Q. Le, Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br. J. Cancer. 118(12), 1539\u20131548 (2018). https:\/\/doi.org\/10.1038\/s41416-018-0073-2","journal-title":"Br. J. Cancer"},{"issue":"3","key":"1054_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"C.E. Prada","year":"2012","unstructured":"C.E. Prada, F.A. Rangwala, L.J. Martin, A.M. Lovell, H.M. Saal, E.K. Schorry, R.J. Hopkin, Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J. Pediatr. 160(3), 461\u2013467 (2012). https:\/\/doi.org\/10.1016\/j.jpeds.2011.08.051","journal-title":"J. Pediatr"},{"issue":"4","key":"1054_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"V.F. Mautner","year":"2008","unstructured":"V.F. Mautner, F.A. Asuagbor, E. Dombi, C. Funsterer, L. Kluwe, R. Wenzel, B.C. Widemann, J.M. Friedman, Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro. Oncol. 10(4), 593\u2013598 (2008). https:\/\/doi.org\/10.1215\/15228517-2008-011","journal-title":"Neuro. Oncol."},{"issue":"2","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/ng0293-122","volume":"3","author":"E. Legius","year":"1993","unstructured":"E. Legius, D.A. Marchuk, F.S. Collins, T.W. Glover, Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 3(2), 122\u2013126 (1993). https:\/\/doi.org\/10.1038\/ng0293-122","journal-title":"Nat. Genet"},{"issue":"1","key":"1054_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","volume":"9","author":"K.J. Radomska","year":"2019","unstructured":"K.J. Radomska, F. Coulpier, A. Gresset, A. Schmitt, A. Debbiche, S. Lemoine, P. Wolkenstein, J.M. Vallat, P. Charnay, P. Topilko, Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov. 9(1), 130\u2013147 (2019). https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0156","journal-title":"Cancer Discov"},{"key":"1054_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev-pathol-011811-132441","volume":"7","author":"K. Staser","year":"2012","unstructured":"K. Staser, F.C. Yang, D.W. Clapp, Pathogenesis of plexiform neurofibroma: tumor-stromal\/hematopoietic interactions in tumor progression. Annu. Rev. Pathol. 7, 469\u2013495 (2012). https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132441","journal-title":"Annu. Rev. Pathol."},{"issue":"18","key":"1054_CR20","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.ejca.2011.05.031","volume":"47","author":"S. Ingham","year":"2011","unstructured":"S. Ingham, S.M. Huson, A. Moran, J. Wylie, M. Leahy, D.G. Evans, Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur. J. Cancer. 47(18), 2723\u20132728 (2011). https:\/\/doi.org\/10.1016\/j.ejca.2011.05.031","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"1054_CR21","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/wnl.58.10.1461","volume":"58","author":"R.J. Packer","year":"2002","unstructured":"R.J. Packer, D.H. Gutmann, A. Rubenstein, D. Viskochil, R.A. Zimmerman, G. Vezina, J. Small, B. Korf, Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology. 58(10), 1461\u20131470 (2002). https:\/\/doi.org\/10.1212\/wnl.58.10.1461","journal-title":"Neurology"},{"issue":"4","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","volume":"6","author":"I. Solares","year":"2021","unstructured":"I. Solares, D. Vinal, M. Morales-Conejo, N. Rodriguez-Salas, J. Feliu, Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open. 6(4), 100223 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2021.100223","journal-title":"ESMO Open"},{"key":"1054_CR23","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"D.H. Gutmann","year":"2017","unstructured":"D.H. Gutmann, R.E. Ferner, R.H. Listernick, B.R. Korf, P.L. Wolters, K.J. Johnson, Neurofibromatosis type 1. Nat. Rev. Dis. Primers. 3, 17004 (2017). https:\/\/doi.org\/10.1038\/nrdp.2017.4","journal-title":"Nat. Rev. Dis. Primers."},{"key":"1054_CR24","doi-asserted-by":"publisher","unstructured":"L.J. Kershner, K. Choi, J. Wu, X. Zhang, M. Perrino, N. Salomonis, J.F. Shern, N. Ratner, Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight. 7(18), (2022). https:\/\/doi.org\/10.1172\/jci.insight.154513","DOI":"10.1172\/jci.insight.154513"},{"issue":"6","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/00005072-199511000-00001","volume":"54","author":"L.J. Metheny","year":"1995","unstructured":"L.J. Metheny, A.J. Cappione, G.R. Skuse, Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. J. Neuropathol. Exp. Neurol. 54(6), 753\u2013760 (1995). https:\/\/doi.org\/10.1097\/00005072-199511000-00001","journal-title":"J. Neuropathol. Exp. Neurol"},{"issue":"10","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"A.M. Gross","year":"2023","unstructured":"A.M. Gross, E. Dombi, P.L. Wolters, A. Baldwin, A. Dufek, K. Herrera, S. Martin, J. Derdak, K.S. Heisey, P.M. Whitcomb, S.M. Steinberg, D.J. Venzon, M.J. Fisher, A. Kim, M. Bornhorst, B.D. Weiss, J.O. Blakeley, M.A. Smith, B.C. Widemann, Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro. Oncol. 25(10), 1883\u20131894 (2023). https:\/\/doi.org\/10.1093\/neuonc\/noad086","journal-title":"Neuro. Oncol."},{"issue":"11","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"A.M. Gross","year":"2022","unstructured":"A.M. Gross, B. Glassberg, P.L. Wolters, E. Dombi, A. Baldwin, M.J. Fisher, A. Kim, M. Bornhorst, B.D. Weiss, J.O. Blakeley, P. Whitcomb, S.M. Paul, S.M. Steinberg, D.J. Venzon, S. Martin, A. Carbonell, K. Heisey, J. Therrien, O. Kapustina, A. Dufek, J. Derdak, M.A. Smith, B.C. Widemann, Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro. Oncol. 24(11), 1978\u20131988 (2022). https:\/\/doi.org\/10.1093\/neuonc\/noac109","journal-title":"Neuro. Oncol."},{"issue":"26","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E. Dombi","year":"2016","unstructured":"E. Dombi, A. Baldwin, L.J. Marcus, M.J. Fisher, B. Weiss, A. Kim, P. Whitcomb, S. Martin, L.E. Aschbacher-Smith, T.A. Rizvi, J. Wu, R. Ershler, P. Wolters, J. Therrien, J. Glod, J.B. Belasco, E. Schorry, A. Brofferio, A.J. Starosta, A. Gillespie, A.L. Doyle, N. Ratner, B.C. Widemann, Activity of Selumetinib in Neurofibromatosis Type 1-related plexiform neurofibromas. N Engl. J. Med. 375(26), 2550\u20132560 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1605943","journal-title":"N Engl. J. Med"},{"issue":"2","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.anndiagpath.2013.10.007","volume":"18","author":"K. Thway","year":"2014","unstructured":"K. Thway, C. Fisher, Malignant peripheral nerve sheath tumor: pathology and genetics. Ann. Diagn. Pathol. 18(2), 109\u2013116 (2014). https:\/\/doi.org\/10.1016\/j.anndiagpath.2013.10.007","journal-title":"Ann. Diagn. Pathol."},{"issue":"6","key":"1054_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/CCO.0000000000000576","volume":"31","author":"M. Eoli","year":"2019","unstructured":"M. Eoli, V. Saletti, G. Finocchiaro, Neurological malignancies in neurofibromatosis type 1. Curr. Opin. Oncol. 31(6), 554\u2013561 (2019). https:\/\/doi.org\/10.1097\/CCO.0000000000000576","journal-title":"Curr. Opin. Oncol"},{"issue":"17","key":"1054_CR31","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","volume":"41","author":"B.N. Somatilaka","year":"2022","unstructured":"B.N. Somatilaka, A. Sadek, R.M. McKay, L.Q. Le, Malignant peripheral nerve sheath tumor: models, biology, and translation. Oncogene. 41(17), 2405\u20132421 (2022). https:\/\/doi.org\/10.1038\/s41388-022-02290-1","journal-title":"Oncogene"},{"key":"1054_CR32","doi-asserted-by":"publisher","first-page":"756395","DOI":"10.1155\/2009\/756395","volume":"2009","author":"D.E. Porter","year":"2009","unstructured":"D.E. Porter, V. Prasad, L. Foster, G.F. Dall, R. Birch, R.J. Grimer, Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis Type 1-associated tumours. Sarcoma. 2009, 756395 (2009). https:\/\/doi.org\/10.1155\/2009\/756395","journal-title":"Sarcoma"},{"issue":"3","key":"1054_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"C.C. Stucky","year":"2012","unstructured":"C.C. Stucky, K.N. Johnson, R.J. Gray, B.A. Pockaj, I.T. Ocal, P.S. Rose, N. Wasif, Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann. Surg. Oncol. 19(3), 878\u2013885 (2012). https:\/\/doi.org\/10.1245\/s10434-011-1978-7","journal-title":"Ann. Surg. Oncol"},{"issue":"5","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"D.G. Evans","year":"2002","unstructured":"D.G. Evans, M.E. Baser, J. McGaughran, S. Sharif, E. Howard, A. Moran, Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39(5), 311\u2013314 (2002). https:\/\/doi.org\/10.1136\/jmg.39.5.311","journal-title":"J. Med. Genet."},{"key":"1054_CR35","doi-asserted-by":"publisher","first-page":"7429697","DOI":"10.1155\/2017\/7429697","volume":"2017","author":"A. Kim","year":"2017","unstructured":"A. Kim, D.R. Stewart, K.M. Reilly, D. Viskochil, M.M. Miettinen, B.C. Widemann, Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017, 7429697 (2017). https:\/\/doi.org\/10.1155\/2017\/7429697","journal-title":"Sarcoma"},{"issue":"2","key":"1054_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/neuonc\/nos287","volume":"15","author":"M. Kolberg","year":"2013","unstructured":"M. Kolberg, M. Holand, T.H. Agesen, H.R. Brekke, K. Liestol, K.S. Hall, F. Mertens, P. Picci, S. Smeland, R.A. Lothe, Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro. Oncol. 15(2), 135\u2013147 (2013). https:\/\/doi.org\/10.1093\/neuonc\/nos287","journal-title":"Neuro. Oncol."},{"issue":"1","key":"1054_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","volume":"126","author":"K.L. Watson","year":"2017","unstructured":"K.L. Watson, G.A. Al Sannaa, C.M. Kivlin, D.R. Ingram, S.M. Landers, C.L. Roland, J.N. Cormier, K.K. Hunt, B.W. Feig, B. Ashleigh Guadagnolo, A.J. Bishop, W.L. Wang, J.M. Slopis, I.E. McCutcheon, A.J. Lazar, K.E. Torres, Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J. Neurosurg. 126(1), 319\u2013329 (2017). https:\/\/doi.org\/10.3171\/2015.12.JNS152443","journal-title":"J. Neurosurg"},{"issue":"4","key":"1054_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nec.2008.07.004","volume":"19","author":"G. Gupta","year":"2008","unstructured":"G. Gupta, A. Mammis, A. Maniker, Malignant peripheral nerve sheath tumors. Neurosurg. Clin. N. Am. 19(4), 533\u2013543,v (2008). https:\/\/doi.org\/10.1016\/j.nec.2008.07.004","journal-title":"Neurosurg. Clin. N. Am"},{"issue":"4","key":"1054_CR39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","volume":"11","author":"B.C. Widemann","year":"2009","unstructured":"B.C. Widemann, Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr. Oncol. Rep. 11(4), 322\u2013328 (2009). https:\/\/doi.org\/10.1007\/s11912-009-0045-z","journal-title":"Curr. Oncol. Rep"},{"issue":"Suppl 1","key":"1054_CR40","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/noajnl\/vdz047","volume":"2","author":"B.C. Prudner","year":"2020","unstructured":"B.C. Prudner, T. Ball, R. Rathore, A.C. Hirbe, Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives. Neurooncol. Adv. 2(Suppl 1), i40\u2013i49 (2020). https:\/\/doi.org\/10.1093\/noajnl\/vdz047","journal-title":"Neurooncol. Adv"},{"issue":"9","key":"1054_CR41","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","volume":"22","author":"S. Akshintala","year":"2020","unstructured":"S. Akshintala, A. Baldwin, D.J. Liewehr, A. Goodwin, J.O. Blakeley, A.M. Gross, S.M. Steinberg, E. Dombi, B.C. Widemann, Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro Oncol. 22(9), 1368\u20131378 (2020). https:\/\/doi.org\/10.1093\/neuonc\/noaa053","journal-title":"Neuro Oncol."},{"issue":"5","key":"1054_CR42","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3171\/2019.7.JNS191353","volume":"133","author":"C.N. Nelson","year":"2020","unstructured":"C.N. Nelson, E. Dombi, J.S. Rosenblum, M.M. Miettinen, T.J. Lehky, P.O. Whitcomb, C. Hayes, G. Scott, S. Benzo, B.C. Widemann, P. Chittiboina, Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J. Neurosurg. 133(5), 1516\u20131526 (2020)","journal-title":"J. Neurosurg"},{"issue":"7","key":"1054_CR43","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1541-7786.MCR-19-0147","volume":"17","author":"J. Korfhage","year":"2019","unstructured":"J. Korfhage, D.B. Lombard, Malignant peripheral nerve sheath tumors: from epigenome to bedside. Mol. Cancer Res. 17(7), 1417\u20131428 (2019). https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0147","journal-title":"Mol. Cancer Res"},{"issue":"2","key":"1054_CR44","doi-asserted-by":"publisher","first-page":"106096","DOI":"10.1016\/j.isci.2023.106096","volume":"26","author":"M. Magallon-Lorenz","year":"2023","unstructured":"M. Magallon-Lorenz, E. Terribas, S. Ortega-Bertran, E. Creus-Bachiller, M. Fernandez, G. Requena, I. Rosas, H. Mazuelas, I. Uriarte-Arrazola, A. Negro, T. Lausova, E. Castellanos, I. Blanco, G. DeVries, H. Kawashima, E. Legius, H. Brems, V. Mautner, L. Kluwe, N. Ratner, M. Wallace, J. Fernandez-Rodriguez, C. Lazaro, J.A. Fletcher, D. Reuss, M. Carrio, B. Gel, E. Serra, Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 26(2), 106096 (2023). https:\/\/doi.org\/10.1016\/j.isci.2023.106096","journal-title":"iScience"},{"issue":"3","key":"1054_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00234-005-0033-4","volume":"48","author":"V.F. Mautner","year":"2006","unstructured":"V.F. Mautner, M. Hartmann, L. Kluwe, R.E. Friedrich, C. Funsterer, MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology. 48(3), 160\u2013165 (2006). https:\/\/doi.org\/10.1007\/s00234-005-0033-4","journal-title":"Neuroradiology"},{"issue":"11","key":"1054_CR46","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"M.J. Fisher","year":"2022","unstructured":"M.J. Fisher, J.O. Blakeley, B.D. Weiss, E. Dombi, S. Ahlawat, S. Akshintala, A.J. Belzberg, M. Bornhorst, M.A. Bredella, W. Cai, R.E. Ferner, A.M. Gross, G.J. Harris, R. Listernick, I. Ly, S. Martin, V.F. Mautner, J.M. Salamon, K.E. Salerno, R.J. Spinner, V. Staedtke, N.J. Ullrich, M. Upadhyaya, P.L. Wolters, K. Yohay, B.C. Widemann, Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro. Oncol. 24(11), 1827\u20131844 (2022). https:\/\/doi.org\/10.1093\/neuonc\/noac146","journal-title":"Neuro. Oncol."},{"key":"1054_CR47","doi-asserted-by":"publisher","unstructured":"M.M. Miettinen, C.R. Antonescu, C.D.M. Fletcher, A. Kim, A.J. Lazar, M.M. Quezado, K.M. Reilly, A. Stemmer-Rachamimov, D.R. Stewart, D. Viskochil, B. Widemann, A. Perry, Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum. Pathol. 2017;67:1\u201310. https:\/\/doi.org\/10.1016\/j.humpath.2017.05.010","DOI":"10.1016\/j.humpath.2017.05.010"},{"issue":"4","key":"1054_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jso.20971","volume":"97","author":"S.R. Grobmyer","year":"2008","unstructured":"S.R. Grobmyer, J.D. Reith, A. Shahlaee, C.H. Bush, S.N. Hochwald, Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J. Surg. Oncol. 97(4), 340\u2013349 (2008). https:\/\/doi.org\/10.1002\/jso.20971","journal-title":"J. Surg. Oncol."},{"issue":"6","key":"1054_CR49","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","volume":"20","author":"C.S. Higham","year":"2018","unstructured":"C.S. Higham, E. Dombi, A. Rogiers, S. Bhaumik, S. Pans, S.E.J. Connor, M. Miettinen, R. Sciot, R. Tirabosco, H. Brems, A. Baldwin, E. Legius, B.C. Widemann, R.E. Ferner, The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro. Oncol. 20(6), 818\u2013825 (2018). https:\/\/doi.org\/10.1093\/neuonc\/noy013","journal-title":"Neuro. Oncol."},{"issue":"12","key":"1054_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/gcc.20921","volume":"50","author":"E. Beert","year":"2011","unstructured":"E. Beert, H. Brems, B. Daniels, I. De Wever, F. Van Calenbergh, J. Schoenaers, M. Debiec-Rychter, O. Gevaert, T. De Raedt, A. Van Den Bruel, T. de Ravel, K. Cichowski, L. Kluwe, V. Mautner, R. Sciot, E. Legius, Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 50(12), 1021\u20131032 (2011). https:\/\/doi.org\/10.1002\/gcc.20921","journal-title":"Genes Chromosomes Cancer"},{"key":"1054_CR51","doi-asserted-by":"publisher","unstructured":"C.G. Lucas, A.M. Gross, C.G. Romo, C.A. Dehner, A.J. Lazar, M. Miettinen, M. Pekmezci, M. Quezado, F.J. Rodriguez, A. Stemmer-Rachamimov, D. Viskochil, A. Perry, Members Symposium on Atypical Neurofibroma: state of the Science. Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis type 1 (NF1). Neuro. Oncol. (2024). https:\/\/doi.org\/10.1093\/neuonc\/noae235","DOI":"10.1093\/neuonc\/noae235"},{"issue":"11","key":"1054_CR52","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/WNL.0000000000008092","volume":"93","author":"S. Ahlawat","year":"2019","unstructured":"S. Ahlawat, J.O. Blakeley, F.J. Rodriguez, L.M. Fayad, Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 93(11), e1076\u2013e1084 (2019). https:\/\/doi.org\/10.1212\/WNL.0000000000008092","journal-title":"Neurology"},{"issue":"8","key":"1054_CR53","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3174\/ajnr.A3910","volume":"35","author":"S. Demehri","year":"2014","unstructured":"S. Demehri, A. Belzberg, J. Blakeley, L.M. Fayad, Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol. 35(8), 1615\u20131620 (2014). https:\/\/doi.org\/10.3174\/ajnr.A3910","journal-title":"AJNR Am J Neuroradiol"},{"key":"1054_CR54","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.wneu.2021.09.130","volume":"157","author":"H. Koike","year":"2022","unstructured":"H. Koike, Y. Nishida, S. Ito, Y. Shimoyama, K. Ikuta, H. Urakawa, T. Sakai, K. Shimizu, K. Ito, S. Imagama, Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of benign from Malignant Peripheral Nerve Sheath Tumors. World Neurosurg. 157, e207\u2013e214 (2022). https:\/\/doi.org\/10.1016\/j.wneu.2021.09.130","journal-title":"World Neurosurg."},{"key":"1054_CR55","doi-asserted-by":"publisher","first-page":"6162182","DOI":"10.1155\/2016\/6162182","volume":"2016","author":"D. Tovmassian","year":"2016","unstructured":"D. Tovmassian, M. Abdul Razak, K. London, The Role of [(18)F]FDG-PET\/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1. Int. J. Surg. Oncol. 2016, 6162182 (2016). https:\/\/doi.org\/10.1155\/2016\/6162182","journal-title":"Int. J. Surg. Oncol"},{"issue":"11","key":"1054_CR56","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/MNM.0000000000000889","volume":"39","author":"M. Brinkman","year":"2018","unstructured":"M. Brinkman, S. Jentjens, K. Boone, M. Anten, P.J. Nelemans, Mjpg van Kroonenburgh, Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET\/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1. Nucl. Med. Commun. 39(11), 961\u2013968 (2018). https:\/\/doi.org\/10.1097\/MNM.0000000000000889","journal-title":"Nucl. Med. Commun"},{"issue":"10","key":"1054_CR57","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1177\/0284185116684674","volume":"58","author":"H.Y. Kim","year":"2017","unstructured":"H.Y. Kim, J.Y. Hwang, H.J. Kim, Y.K. Kim, J. Cha, G.M. Park, S.T. Kim, CT, MRI, and (18)F-FDG PET\/CT findings of malignant peripheral nerve sheath tumor of the head and neck. Acta Radiol. 58(10), 1222\u20131230 (2017). https:\/\/doi.org\/10.1177\/0284185116684674","journal-title":"Acta Radiol"},{"issue":"3","key":"1054_CR58","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1007\/s00330-020-07234-5","volume":"31","author":"J.S. Yun","year":"2021","unstructured":"J.S. Yun, M.H. Lee, S.M. Lee, J.S. Lee, H.J. Kim, S.J. Lee, H.W. Chung, S.H. Lee, M.J. Shin, Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI. Eur. Radiol. 31(3), 1548\u20131557 (2021). https:\/\/doi.org\/10.1007\/s00330-020-07234-5","journal-title":"Eur. Radiol"},{"issue":"1","key":"1054_CR59","doi-asserted-by":"publisher","first-page":"vdae021","DOI":"10.1093\/noajnl\/vdae021","volume":"6","author":"I. Ristow","year":"2024","unstructured":"I. Ristow, M.G. Kaul, M. Stark, A. Zapf, C. Riedel, A. Lenz, V.F. Mautner, S. Farschtschi, I. Apostolova, G. Adam, P. Bannas, J. Salamon, L. Well, Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI. Neurooncol. Adv. 6(1), vdae021 (2024). https:\/\/doi.org\/10.1093\/noajnl\/vdae021","journal-title":"Neurooncol. Adv"},{"issue":"Supplement","key":"1054_CR60","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.4103\/0028-3886.250697","volume":"67","author":"D. Garozzo","year":"2019","unstructured":"D. Garozzo, Peripheral nerve tumors in neurofibromatosis 1: an overview on management and indications for surgical treatment in our experience. Neurol. India. 67(Supplement), S38\u2013S44 (2019). https:\/\/doi.org\/10.4103\/0028-3886.250697","journal-title":"Neurol. India"},{"issue":"5","key":"1054_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11523-024-01078-5","volume":"19","author":"N. Somaiah","year":"2024","unstructured":"N. Somaiah, B. Paudyal, R.E. Winkler, B.A. Van Tine, A.C. Hirbe, Malignant peripheral nerve sheath tumor, a heterogeneous, aggressive cancer with diverse biomarkers and no targeted standard of care: review of the literature and ongoing investigational agents. Target Oncol. 19(5), 665\u2013678 (2024). https:\/\/doi.org\/10.1007\/s11523-024-01078-5","journal-title":"Target Oncol"},{"key":"1054_CR62","unstructured":"L. Messersmith, K. Krauland, Neurofibroma. StatPearls. Treasure Island (FL), 2024"},{"key":"1054_CR63","doi-asserted-by":"publisher","unstructured":"L.L. Ge, M.Y. Xing, H.B. Zhang, Z.C. Wang, Neurofibroma development in neurofibromatosis Type 1: insights from cellular origin and Schwann cell lineage development. Cancers (Basel). 14(18), (2022). https:\/\/doi.org\/10.3390\/cancers14184513","DOI":"10.3390\/cancers14184513"},{"issue":"1","key":"1054_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF00203733","volume":"427","author":"L.G. Kindblom","year":"1995","unstructured":"L.G. Kindblom, M. Ahlden, J.M. Meis-Kindblom, G. Stenman, Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch. 427(1), 19\u201326 (1995). https:\/\/doi.org\/10.1007\/BF00203733","journal-title":"Virchows Arch."},{"key":"1054_CR65","doi-asserted-by":"publisher","unstructured":"K. Tekavec, T. Svara, T. Knific, M. Gombac, C. Cantile, Histopathological and immunohistochemical evaluation of Canine nerve sheath tumors and proposal for an updated classification. Vet. Sci. 9(5), (2022). https:\/\/doi.org\/10.3390\/vetsci9050204","DOI":"10.3390\/vetsci9050204"},{"issue":"3","key":"1054_CR66","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/PAS.0000000000000978","volume":"42","author":"A. Elsensohn","year":"2018","unstructured":"A. Elsensohn, J. Shiu, N. Grove, A.M. Hosking, R. Barr, S. de Feraudy, Distinguishing neurofibroma from desmoplastic melanoma: the value of p53. Am. J. Surg. Pathol. 42(3), 372\u2013375 (2018). https:\/\/doi.org\/10.1097\/PAS.0000000000000978","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"1054_CR67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/ajcp\/106.3.282","volume":"106","author":"K.C. Halling","year":"1996","unstructured":"K.C. Halling, B.W. Scheithauer, A.C. Halling, A.G. Nascimento, S.C. Ziesmer, P.C. Roche, P.C. Wollan, p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am. J. Clin. Pathol. 106(3), 282\u2013288 (1996). https:\/\/doi.org\/10.1093\/ajcp\/106.3.282","journal-title":"Am. J. Clin. Pathol"},{"issue":"6","key":"1054_CR68","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0002-9440(10)65507-1","volume":"155","author":"G.P. Nielsen","year":"1999","unstructured":"G.P. Nielsen, A.O. Stemmer-Rachamimov, Y. Ino, M.B. Moller, A.E. Rosenberg, D.N. Louis, Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A\/p16 inactivation. Am. J. Pathol. 155(6), 1879\u20131884 (1999). https:\/\/doi.org\/10.1016\/S0002-9440(10)65507-1","journal-title":"Am. J. Pathol."},{"issue":"4","key":"1054_CR69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.MP.0000062654.83617.B7","volume":"16","author":"T. Hirose","year":"2003","unstructured":"T. Hirose, T. Tani, T. Shimada, K. Ishizawa, S. Shimada, T. Sano, Immunohistochemical demonstration of EMA\/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors. Mod. Pathol. 16(4), 293\u2013298 (2003). https:\/\/doi.org\/10.1097\/01.MP.0000062654.83617.B7","journal-title":"Mod. Pathol"},{"issue":"12","key":"1054_CR70","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/00000478-199712000-00006","volume":"21","author":"B.T. Lin","year":"1997","unstructured":"B.T. Lin, L.M. Weiss, L.J. Medeiros, Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am. J. Surg. Pathol. 21(12), 1443\u20131449 (1997). https:\/\/doi.org\/10.1097\/00000478-199712000-00006","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"1054_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0560.2009.01293.x","volume":"37","author":"C.H. Jokinen","year":"2010","unstructured":"C.H. Jokinen, Z.B. Argenyi, Atypical neurofibroma of the skin and subcutaneous tissue: clinicopathologic analysis of 11 cases. J. Cutan. Pathol. 37(1), 35\u201342 (2010). https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01293.x","journal-title":"J. Cutan. Pathol"},{"issue":"2","key":"1054_CR72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-010-0385-4","volume":"103","author":"U. Naber","year":"2011","unstructured":"U. Naber, R.E. Friedrich, M. Glatzel, V.F. Mautner, C. Hagel, Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma. J. Neurooncol. 103(2), 239\u2013245 (2011). https:\/\/doi.org\/10.1007\/s11060-010-0385-4","journal-title":"J. Neurooncol."},{"issue":"9","key":"1054_CR73","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/neuonc\/noad053","volume":"25","author":"C. Kresbach","year":"2023","unstructured":"C. Kresbach, M. Dottermusch, A. Eckhardt, I. Ristow, P. Paplomatas, L. Altendorf, A.K. Wefers, M. Bockmayr, S. Belakhoua, I. Tran, L. Pohl, S. Neyazi, H. Bode, S. Farschtschi, L. Well, R.E. Friedrich, D. Reuss, M. Snuderl, C. Hagel, V.F. Mautner, U. Schuller, Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Neuro. Oncol. 25(9), 1644\u20131655 (2023). https:\/\/doi.org\/10.1093\/neuonc\/noad053","journal-title":"Neuro. Oncol."},{"issue":"6","key":"1054_CR74","first-page":"871","volume":"24","author":"R.E. Friedrich","year":"2010","unstructured":"R.E. Friedrich, T. Derlin, C. Hagel, Atypical plexiform neurofibroma in NF1 with high standardised uptake value (SUV) in positron-emission tomography (PET) expressing podoplanin. In Vivo. 24(6), 871\u2013876 (2010)","journal-title":"In Vivo"},{"issue":"3","key":"1054_CR75","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/neuros\/nyab021","volume":"88","author":"S.M. Belakhoua","year":"2021","unstructured":"S.M. Belakhoua, F.J. Rodriguez, Diagnostic pathology of tumors of peripheral nerve. Neurosurgery. 88(3), 443\u2013456 (2021). https:\/\/doi.org\/10.1093\/neuros\/nyab021","journal-title":"Neurosurgery"},{"issue":"2","key":"1054_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1046\/j.1365-2559.2001.01176.x","volume":"39","author":"T. Watanabe","year":"2001","unstructured":"T. Watanabe, Y. Oda, S. Tamiya, N. Kinukawa, K. Masuda, M. Tsuneyoshi, Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology. 39(2), 187\u2013197 (2001). https:\/\/doi.org\/10.1046\/j.1365-2559.2001.01176.x","journal-title":"Histopathology"},{"issue":"1","key":"1054_CR77","doi-asserted-by":"publisher","first-page":"vdaa131","DOI":"10.1093\/noajnl\/vdaa131","volume":"2","author":"C.G. Lucas","year":"2020","unstructured":"C.G. Lucas, H.N. Vasudevan, W.C. Chen, S.T. Magill, S.E. Braunstein, L. Jacques, S. Dahiya, F.J. Rodriguez, A.E. Horvai, A. Perry, M. Pekmezci, D.R. Raleigh, Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival. Neurooncol. Adv. 2(1), vdaa131 (2020). https:\/\/doi.org\/10.1093\/noajnl\/vdaa131","journal-title":"Neurooncol. Adv"},{"issue":"8","key":"1054_CR78","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1593\/neo.07304","volume":"9","author":"N. Holtkamp","year":"2007","unstructured":"N. Holtkamp, I. Atallah, A.F. Okuducu, J. Mucha, C. Hartmann, V.F. Mautner, R.E. Friedrich, C. Mawrin, A. von Deimling, MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia. 9(8), 671\u2013677 (2007). https:\/\/doi.org\/10.1593\/neo.07304","journal-title":"Neoplasia"},{"issue":"10","key":"1054_CR79","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/00000478-200310000-00006","volume":"27","author":"H. Zhou","year":"2003","unstructured":"H. Zhou, C.M. Coffin, S.L. Perkins, S.R. Tripp, M. Liew, D.H. Viskochil, Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle\/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am. J. Surg. Pathol. 27(10), 1337\u20131345 (2003). https:\/\/doi.org\/10.1097\/00000478-200310000-00006","journal-title":"Am. J. Surg. Pathol."},{"issue":"16","key":"1054_CR80","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/hmg\/ddz095","volume":"28","author":"S.D. Rhodes","year":"2019","unstructured":"S.D. Rhodes, Y. He, A. Smith, L. Jiang, Q. Lu, J. Mund, X. Li, W. Bessler, S. Qian, W. Dyer, G.E. Sandusky, A.E. Horvai, A.E. Armstrong, D.W. Clapp, Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum. Mol. Genet. 28(16), 2752\u20132762 (2019). https:\/\/doi.org\/10.1093\/hmg\/ddz095","journal-title":"Hum. Mol. Genet"},{"issue":"21","key":"1054_CR81","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-19-1429","volume":"80","author":"K.E. Chaney","year":"2020","unstructured":"K.E. Chaney, M.R. Perrino, L.J. Kershner, A.V. Patel, J. Wu, K. Choi, T.A. Rizvi, E. Dombi, S. Szabo, D.A. Largaespada, N. Ratner, Cdkn2a loss in a model of neurofibroma demonstrates stepwise tumor progression to atypical neurofibroma and MPNST. Cancer Res. 80(21), 4720\u20134730 (2020). https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1429","journal-title":"Cancer Res"},{"issue":"11","key":"1054_CR82","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W. Lee","year":"2014","unstructured":"W. Lee, S. Teckie, T. Wiesner, L. Ran, C.N. Prieto Granada, M. Lin, S. Zhu, Z. Cao, Y. Liang, A. Sboner, W.D. Tap, J.A. Fletcher, K.H. Huberman, L.X. Qin, A. Viale, S. Singer, D. Zheng, M.F. Berger, Y. Chen, C.R. Antonescu, P. Chi, PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46(11), 1227\u20131232 (2014). https:\/\/doi.org\/10.1038\/ng.3095","journal-title":"Nat. Genet"},{"issue":"2","key":"1054_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/path.5507","volume":"252","author":"I. Lyskjaer","year":"2020","unstructured":"I. Lyskjaer, D. Lindsay, R. Tirabosco, C.D. Steele, P. Lombard, A.C. Strobl, A.M. Rocha, C. Davies, H. Ye, E. Bekers, J. Ingruber, M. Lechner, F. Amary, N. Pillay, A.M. Flanagan, H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. J. Pathol. 252(2), 151\u2013164 (2020). https:\/\/doi.org\/10.1002\/path.5507","journal-title":"J. Pathol"},{"issue":"1","key":"1054_CR84","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1097\/RLU.0b013e318266ce84","volume":"38","author":"T. Derlin","year":"2013","unstructured":"T. Derlin, K. Tornquist, S. Munster, I. Apostolova, C. Hagel, R.E. Friedrich, U. Wedegartner, V.F. Mautner, Comparative effectiveness of 18F-FDG PET\/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin. Nucl. Med. 38(1), e19\u201325 (2013). https:\/\/doi.org\/10.1097\/RLU.0b013e318266ce84","journal-title":"Clin. Nucl. Med"},{"issue":"3","key":"1054_CR85","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/cas.14802","volume":"112","author":"Y. Nishida","year":"2021","unstructured":"Y. Nishida, K. Ikuta, S. Ito, H. Urakawa, T. Sakai, H. Koike, K. Ito, S. Imagama, Limitations and benefits of FDG-PET\/CT in NF1 patients with nerve sheath tumors: a cross-sectional\/longitudinal study. Cancer Sci. 112(3), 1114\u20131122 (2021). https:\/\/doi.org\/10.1111\/cas.14802","journal-title":"Cancer Sci"},{"issue":"5","key":"1054_CR86","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00247-009-1434-z","volume":"40","author":"S.C. Chawla","year":"2010","unstructured":"S.C. Chawla, N. Federman, D. Zhang, K. Nagata, S. Nuthakki, M. McNitt-Gray, M.I. Boechat, Estimated cumulative radiation dose from PET\/CT in children with malignancies: a 5-year retrospective review. Pediatr. Radiol. 40(5), 681\u2013686 (2010). https:\/\/doi.org\/10.1007\/s00247-009-1434-z","journal-title":"Pediatr. Radiol"},{"issue":"3","key":"1054_CR87","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-018-4227-5","volume":"46","author":"C.P. Reinert","year":"2019","unstructured":"C.P. Reinert, M.U. Schuhmann, B. Bender, I. Gugel, C. la Fougere, J. Schafer, S. Gatidis, Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET\/MRI. Eur. J. Nucl. Med. Mol. Imaging. 46(3), 776\u2013787 (2019). https:\/\/doi.org\/10.1007\/s00259-018-4227-5","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1054_CR88","doi-asserted-by":"publisher","first-page":"898971","DOI":"10.3389\/fonc.2022.898971","volume":"12","author":"J. Liu","year":"2022","unstructured":"J. Liu, J.N. Huang, M.H. Wang, Z.Y. Ni, W.H. Jiang, M. Chung, C.J. Wei, Z.C. Wang, Image-based differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis Type 1. Front. Oncol. 12, 898971 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.898971","journal-title":"Front. Oncol"},{"issue":"7 Suppl 1","key":"1054_CR89","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1212\/WNL.0000000000002929","volume":"87","author":"S. Ahlawat","year":"2016","unstructured":"S. Ahlawat, L.M. Fayad, M.S. Khan, M.A. Bredella, G.J. Harris, D.G. Evans, S. Farschtschi, M.A. Jacobs, A. Chhabra, J.M. Salamon, R. Wenzel, V.F. Mautner, E. Dombi, W. Cai, S.R. Plotkin, J.O. Blakeley, M.R. I, Committee for the REiNS international collaboration whole body, R. EiNS international collaboration members. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 87(7 Suppl 1), S31\u201339 (2016). https:\/\/doi.org\/10.1212\/WNL.0000000000002929","journal-title":"Neurology"},{"issue":"3","key":"1054_CR90","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.114.142372","volume":"56","author":"A. Chirindel","year":"2015","unstructured":"A. Chirindel, M. Chaudhry, J.O. Blakeley, R. Wahl, 18F-FDG PET\/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J. Nucl. Med. 56(3), 379\u2013385 (2015). https:\/\/doi.org\/10.2967\/jnumed.114.142372","journal-title":"J. Nucl. Med"},{"issue":"5","key":"1054_CR91","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-012-2314-6","volume":"40","author":"J. Salamon","year":"2013","unstructured":"J. Salamon, T. Derlin, P. Bannas, J.D. Busch, J. Herrmann, M. Bockhorn, C. Hagel, R.E. Friedrich, G. Adam, V.F. Mautner, Evaluation of intratumoural heterogeneity on (1)(8)F-FDG PET\/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur. J. Nucl. Med. Mol. Imaging. 40(5), 685\u2013692 (2013). https:\/\/doi.org\/10.1007\/s00259-012-2314-6","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"1054_CR92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","volume":"68","author":"R.E. Ferner","year":"2000","unstructured":"R.E. Ferner, J.D. Lucas, M.J. O\u2019Doherty, R.A. Hughes, M.A. Smith, B.F. Cronin, J. Bingham, Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J. Neurol. Neurosurg. Psychiatry. 68(3), 353\u2013357 (2000). https:\/\/doi.org\/10.1136\/jnnp.68.3.353","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"1054_CR93","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ana.410310515","volume":"31","author":"D.H. Gutmann","year":"1992","unstructured":"D.H. Gutmann, F.S. Collins, Recent progress toward understanding the molecular biology of von Recklinghausen neurofibromatosis. Ann. Neurol. 31(5), 555\u2013561 (1992). https:\/\/doi.org\/10.1002\/ana.410310515","journal-title":"Ann. Neurol"},{"issue":"1","key":"1054_CR94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/gcc.22997","volume":"61","author":"M. Riva","year":"2022","unstructured":"M. Riva, D. Martorana, V. Uliana, E. Caleffi, E. Boschi, L. Garavelli, G. Ponti, L. Sangiorgi, C. Graziano, S. Bigoni, L.M. Rocchetti, S. Madeo, F. Soli, E. Grosso, D. Carli, M. Goldoni, F. Pisani, A. Percesepe, Recurrent NF1 gene variants and their genotype\/phenotype correlations in patients with Neurofibromatosis type I. Genes Chromosomes Cancer. 61(1), 10\u201321 (2022). https:\/\/doi.org\/10.1002\/gcc.22997","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"1054_CR95","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I. Cortes-Ciriano","year":"2023","unstructured":"I. Cortes-Ciriano, C.D. Steele, K. Piculell, A. Al-Ibraheemi, V. Eulo, M.M. Bui, A. Chatzipli, B.C. Dickson, D.C. Borcherding, A. Feber, A. Galor, J. Hart, K.B. Jones, J.T. Jordan, R.H. Kim, D. Lindsay, C. Miller, Y. Nishida, P.Z. Proszek, J. Serrano, R.T. Sundby, J.J. Szymanski, N.J. Ullrich, D. Viskochil, X. Wang, M. Snuderl, P.J. Park, A.M. Flanagan, A.C. Hirbe, N. Pillay, D.T. Miller, Mpnst Consortium Genomics of, Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. Cancer Discov. 13(3), 654\u2013671 (2023). https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0786","journal-title":"Cancer Discov"},{"issue":"5","key":"1054_CR96","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1034\/j.1399-0004.2002.620501.x","volume":"62","author":"T. Tucker","year":"2002","unstructured":"T. Tucker, J.M. Friedman, Pathogenesis of hereditary tumors: beyond the \u201ctwo-hit\u201d hypothesis. Clin. Genet. 62(5), 345\u2013357 (2002). https:\/\/doi.org\/10.1034\/j.1399-0004.2002.620501.x","journal-title":"Clin. Genet"},{"issue":"1","key":"1054_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/humu.20601","volume":"29","author":"M. Upadhyaya","year":"2008","unstructured":"M. Upadhyaya, L. Kluwe, G. Spurlock, B. Monem, E. Majounie, K. Mantripragada, M. Ruggieri, N. Chuzhanova, D.G. Evans, R. Ferner, N. Thomas, A. Guha, V. Mautner, Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum. Mutat. 29(1), 74\u201382 (2008). https:\/\/doi.org\/10.1002\/humu.20601","journal-title":"Hum. Mutat."},{"issue":"5","key":"1054_CR98","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1086\/374821","volume":"72","author":"T. De Raedt","year":"2003","unstructured":"T. De Raedt, H. Brems, P. Wolkenstein, D. Vidaud, S. Pilotti, F. Perrone, V. Mautner, S. Frahm, R. Sciot, E. Legius, Elevated risk for MPNST in NF1 microdeletion patients. Am. J. Hum. Genet. 72(5), 1288\u20131292 (2003). https:\/\/doi.org\/10.1086\/374821","journal-title":"Am. J. Hum. Genet"},{"issue":"4","key":"1054_CR99","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0092-8674(01)00245-8","volume":"104","author":"K. Cichowski","year":"2001","unstructured":"K. Cichowski, T. Jacks, NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104(4), 593\u2013604 (2001). https:\/\/doi.org\/10.1016\/s0092-8674(01)00245-8","journal-title":"Cell"},{"issue":"4","key":"1054_CR100","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R. Ballester","year":"1990","unstructured":"R. Ballester, D. Marchuk, M. Boguski, A. Saulino, R. Letcher, M. Wigler, F. Collins, The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 63(4), 851\u2013859 (1990). https:\/\/doi.org\/10.1016\/0092-8674(90)90151-4","journal-title":"Cell"},{"issue":"5","key":"1054_CR101","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/path.2494","volume":"217","author":"I. Bottillo","year":"2009","unstructured":"I. Bottillo, T. Ahlquist, H. Brekke, S.A. Danielsen, E. van den Berg, F. Mertens, R.A. Lothe, B. Dallapiccola, Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J. Pathol. 217(5), 693\u2013701 (2009). https:\/\/doi.org\/10.1002\/path.2494","journal-title":"J. Pathol"},{"issue":"1","key":"1054_CR102","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1038\/s41598-021-85055-2","volume":"11","author":"J.F. Longo","year":"2021","unstructured":"J.F. Longo, S.N. Brosius, I. Znoyko, V.A. Alers, D.P. Jenkins, R.C. Wilson, A.J. Carroll, D.J. Wolff, K.A. Roth, S.L. Carroll, Establishment and genomic characterization of a sporadic malignant peripheral nerve sheath tumor cell line. Sci. Rep. 11(1), 5690 (2021). https:\/\/doi.org\/10.1038\/s41598-021-85055-2","journal-title":"Sci. Rep."},{"key":"1054_CR103","doi-asserted-by":"publisher","unstructured":"E.Y. Kao, K.M. Wakeman, Y. Wu, J.M. Gross, E.Y. Chen, R.W. Ricciotti, Y.J. Liu, J.G. Mantilla, Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR. Hum. Pathol. 129:90\u201397 (2022). https:\/\/doi.org\/10.1016\/j.humpath.2022.08.005","DOI":"10.1016\/j.humpath.2022.08.005"},{"issue":"22","key":"1054_CR104","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/onc.2016.464","volume":"36","author":"A. Pemov","year":"2017","unstructured":"A. Pemov, H. Li, R. Patidar, N.F. Hansen, S. Sindiri, S.W. Hartley, J.S. Wei, A. Elkahloun, S.C. Chandrasekharappa, J.F. Boland, S. Bass, J.C. Mullikin, J. Khan, B.C. Widemann, M.R. Wallace, D.R. Stewart, The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Oncogene. 36(22), 3168\u20133177 (2017). https:\/\/doi.org\/10.1038\/onc.2016.464","journal-title":"Oncogene"},{"issue":"1","key":"1054_CR105","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00401-019-02086-w","volume":"139","author":"Y. Yu","year":"2020","unstructured":"Y. Yu, K. Choi, J. Wu, P.R. Andreassen, P.J. Dexheimer, M. Keddache, H. Brems, R.J. Spinner, J.A. Cancelas, L.J. Martin, M.R. Wallace, E. Legius, K.S. Vogel, N. Ratner, NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathol. 139(1), 157\u2013174 (2020). https:\/\/doi.org\/10.1007\/s00401-019-02086-w","journal-title":"Acta Neuropathol"},{"key":"1054_CR106","doi-asserted-by":"publisher","unstructured":"K.M. Lemberg, J. Wang, C.A. Pratilas, From genes to -Omics: the evolving molecular landscape of malignant peripheral nerve sheath tumor. Genes (Basel). 11(6), (2020). https:\/\/doi.org\/10.3390\/genes11060691","DOI":"10.3390\/genes11060691"},{"issue":"10","key":"1054_CR107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/35096061","volume":"2","author":"C.J. Sherr","year":"2001","unstructured":"C.J. Sherr, The INK4a\/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2(10), 731\u2013737 (2001). https:\/\/doi.org\/10.1038\/35096061","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"1054_CR108","doi-asserted-by":"publisher","unstructured":"J.L. Kohlmeyer, C.A. Kaemmer, S. Umesalma, F.A. Gourronc, A.J. Klingelhutz, D.E. Quelle, RABL6A regulates schwann cell senescence in an RB1-dependent manner. Int. J. Mol. Sci. 22(10), (2021). https:\/\/doi.org\/10.3390\/ijms22105367","DOI":"10.3390\/ijms22105367"},{"issue":"12","key":"1054_CR109","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-19-2706","volume":"26","author":"J.L. Kohlmeyer","year":"2020","unstructured":"J.L. Kohlmeyer, C.A. Kaemmer, C. Pulliam, C.K. Maharjan, A.M. Samayoa, H.J. Major, K.E. Cornick, V. Knepper-Adrian, R. Khanna, J.C. Sieren, M.R. Leidinger, D.K. Meyerholz, K.D. Zamba, J.M. Weimer, R.D. Dodd, B.W. Darbro, M.R. Tanas, D.E. Quelle, RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4\/6 inhibitors. Clin. Cancer. Res. 26(12), 2997\u20133011 (2020). https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2706","journal-title":"Clin. Cancer. Res."},{"issue":"13","key":"1054_CR110","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/0008-5472.CAN-11-4092","volume":"72","author":"V.W. Keng","year":"2012","unstructured":"V.W. Keng, E.P. Rahrmann, A.L. Watson, B.R. Tschida, C.L. Moertel, W.J. Jessen, T.A. Rizvi, M.H. Collins, N. Ratner, D.A. Largaespada, PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res. 72(13), 3405\u20133413 (2012). https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-4092","journal-title":"Cancer Res"},{"issue":"6","key":"1054_CR111","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/labinvest.3780293","volume":"81","author":"S. Birindelli","year":"2001","unstructured":"S. Birindelli, F. Perrone, M. Oggionni, C. Lavarino, B. Pasini, B. Vergani, G.N. Ranzani, M.A. Pierotti, S. Pilotti, Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab. Invest. 81(6), 833\u2013844 (2001). https:\/\/doi.org\/10.1038\/labinvest.3780293","journal-title":"Lab. Invest."},{"issue":"4","key":"1054_CR112","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/gcc.2870100405","volume":"10","author":"E. Legius","year":"1994","unstructured":"E. Legius, H. Dierick, R. Wu, B.K. Hall, P. Marynen, J.J. Cassiman, T.W. Glover, TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 10(4), 250\u2013255 (1994). https:\/\/doi.org\/10.1002\/gcc.2870100405","journal-title":"Genes Chromosomes Cancer"},{"issue":"7330","key":"1054_CR113","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R. Margueron","year":"2011","unstructured":"R. Margueron, D. Reinberg, The Polycomb complex PRC2 and its mark in life. Nature. 469(7330), 343\u2013349 (2011). https:\/\/doi.org\/10.1038\/nature09784","journal-title":"Nature"},{"key":"1054_CR114","doi-asserted-by":"publisher","unstructured":"J.J. Thangaiah, B.E. Westling, A.C. Roden, C. Giannini, M. Tetzlaff, W.C. Cho, A.L. Folpe, Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Ann. Diagn. Pathol. 59:151967 (2022). https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151967","DOI":"10.1016\/j.anndiagpath.2022.151967"},{"issue":"11","key":"1054_CR115","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ng.3116","volume":"46","author":"M. Zhang","year":"2014","unstructured":"M. Zhang, Y. Wang, S. Jones, M. Sausen, K. McMahon, R. Sharma, Q. Wang, A.J. Belzberg, K. Chaichana, G.L. Gallia, Z.L. Gokaslan, G.J. Riggins, J.P. Wolinksy, L.D. Wood, E.A. Montgomery, R.H. Hruban, K.W. Kinzler, N. Papadopoulos, B. Vogelstein, C. Bettegowda, Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 46(11), 1170\u20131172 (2014). https:\/\/doi.org\/10.1038\/ng.3116","journal-title":"Nat. Genet"},{"issue":"Suppl 1","key":"1054_CR116","doi-asserted-by":"publisher","first-page":"i50","DOI":"10.1093\/noajnl\/vdz049","volume":"Adv.2","author":"A. Pemov","year":"2020","unstructured":"A. Pemov, H. Li, W. Presley, M.R. Wallace, D.T. Miller, Genetics of human malignant peripheral nerve sheath tumors. Neurooncol. Adv.2(Suppl 1), i50\u2013i61 (2020). https:\/\/doi.org\/10.1093\/noajnl\/vdz049","journal-title":"Neurooncol"},{"issue":"1","key":"1054_CR117","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/path.4996","volume":"244","author":"G. Jour","year":"2018","unstructured":"G. Jour, N.K. Andeen, R. Al-Rohil, P.P. Aung, M. Mehrotra, D. Duose, B. Hoch, Z. Argenyi, R. Luthra, I.I. Wistuba, V.G. Prieto, Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle\/desmoplastic melanomas. J. Pathol. 244(1), 97\u2013106 (2018). https:\/\/doi.org\/10.1002\/path.4996","journal-title":"J. Pathol"},{"key":"1054_CR118","doi-asserted-by":"publisher","unstructured":"I.R. Cannizzaro, M. Treccani, A. Taiani, E. Ambrosini, S. Busciglio, S. Cesarini, A. Luberto, E. De Sensi, B. Moschella, P. Gismondi, C. Azzoni, L. Bottarelli, G. Giordano, D. Corradi, E.M. Silini, V. Zanatta, F. Cennamo, P. Bertolini, P. Caggiati, D. Martorana, V. Uliana, A. Percesepe, V. Barili, Proof of Concept for Genome Profiling of the Neurofibroma\/Sarcoma Sequence in Neurofibromatosis Type 1. Int. J. Mol. Sci. 25(19), (2024). https:\/\/doi.org\/10.3390\/ijms251910822","DOI":"10.3390\/ijms251910822"},{"issue":"2","key":"1054_CR119","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cancergencyto.2005.07.006","volume":"165","author":"C. Kobayashi","year":"2006","unstructured":"C. Kobayashi, Y. Oda, T. Takahira, T. Izumi, K. Kawaguchi, H. Yamamoto, S. Tamiya, T. Yamada, S. Oda, K. Tanaka, S. Matsuda, Y. Iwamoto, M. Tsuneyoshi, Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet. Cytogenet. 165(2), 98\u2013105 (2006). https:\/\/doi.org\/10.1016\/j.cancergencyto.2005.07.006","journal-title":"Cancer Genet. Cytogenet"},{"key":"1054_CR120","doi-asserted-by":"publisher","unstructured":"C. Dehner, C.I. Moon, X. Zhang, Z. Zhou, C. Miller, H. Xu, X. Wan, K. Yang, J. Mashl, S.J. Gosline, Y. Wang, X. Zhang, A. Godec, P.A. Jones, S. Dahiya, H. Bhatia, T. Primeau, S. Li, K. Pollard, F.J. Rodriguez, L. Ding, C.A. Pratilas, J.F. Shern, A.C. Hirbe, Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight. 6(6), (2021). https:\/\/doi.org\/10.1172\/jci.insight.146351","DOI":"10.1172\/jci.insight.146351"},{"issue":"3","key":"1054_CR121","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ajpath.2015.10.023","volume":"186","author":"S.L. Carroll","year":"2016","unstructured":"S.L. Carroll, The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am. J. Pathol. 186(3), 464\u2013477 (2016). https:\/\/doi.org\/10.1016\/j.ajpath.2015.10.023","journal-title":"Am. J. Pathol."},{"issue":"6","key":"1054_CR122","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/ijc.2910610609","volume":"61","author":"F. Mertens","year":"1995","unstructured":"F. Mertens, A. Rydholm, H.F. Bauer, J. Limon, B. Nedoszytko, A. Szadowska, H. Willen, S. Heim, F. Mitelman, N. Mandahl, Cytogenetic findings in malignant peripheral nerve sheath tumors. Int. J. Cancer. 61(6), 793\u2013798 (1995). https:\/\/doi.org\/10.1002\/ijc.2910610609","journal-title":"Int. J. Cancer"},{"issue":"2","key":"1054_CR123","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A","volume":"26","author":"J.M. Berner","year":"1999","unstructured":"J.M. Berner, T. Sorlie, F. Mertens, J. Henriksen, G. Saeter, N. Mandahl, A. Brogger, O. Myklebost, R.A. Lothe, Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer. 26(2), 151\u2013160 (1999)","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"1054_CR124","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0165-4608(01)00393-4","volume":"128","author":"H. Schmidt","year":"2001","unstructured":"H. Schmidt, H. Taubert, P. Wurl, M. Bache, F. Bartel, H.J. Holzhausen, R. Hinze, Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 128(1), 14\u201323 (2001). https:\/\/doi.org\/10.1016\/s0165-4608(01)00393-4","journal-title":"Cancer Genet. Cytogenet"},{"issue":"8","key":"1054_CR125","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A. Pemov","year":"2019","unstructured":"A. Pemov, N.F. Hansen, S. Sindiri, R. Patidar, C.S. Higham, E. Dombi, M.M. Miettinen, P. Fetsch, H. Brems, S.C. Chandrasekharappa, K. Jones, B. Zhu, J.S. Wei, J.C. Mullikin, M.R. Wallace, J. Khan, E. Legius, B.C. Widemann, D.R. Stewart, Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 21(8), 981\u2013992 (2019). https:\/\/doi.org\/10.1093\/neuonc\/noz028","journal-title":"Neuro Oncol."},{"issue":"9","key":"1054_CR126","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s0046-8177(97)90060-5","volume":"28","author":"U.N. Rao","year":"1997","unstructured":"U.N. Rao, E. Sonmez-Alpan, G.K. Michalopoulos, Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum. Pathol. 28(9), 1066\u20131070 (1997). https:\/\/doi.org\/10.1016\/s0046-8177(97)90060-5","journal-title":"Hum. Pathol."},{"issue":"12","key":"1054_CR127","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-11-0193","volume":"17","author":"K.E. Torres","year":"2011","unstructured":"K.E. Torres, Q.S. Zhu, K. Bill, G. Lopez, M.P. Ghadimi, X. Xie, E.D. Young, J. Liu, T. Nguyen, S. Bolshakov, R. Belousov, S. Wang, G. Lahat, J. Liu, B. Hernandez, A.J. Lazar, D. Lev, Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin. Cancer. Res. 17(12), 3943\u20133955 (2011). https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0193","journal-title":"Clin. Cancer. Res."},{"issue":"13","key":"1054_CR128","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-3167","volume":"78","author":"J.D. Peacock","year":"2018","unstructured":"J.D. Peacock, M.G. Pridgeon, E.A. Tovar, C.J. Essenburg, M. Bowman, Z. Madaj, J. Koeman, E.A. Boguslawski, J. Grit, R.D. Dodd, V. Khachaturov, D.M. Cardona, M. Chen, D.G. Kirsch, F. Maina, R. Dono, M.E. Winn, C.R. Graveel, M.R. Steensma, Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-related malignant peripheral nerve sheath tumors. Cancer Res. 78(13), 3672\u20133687 (2018). https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3167","journal-title":"Cancer Res"},{"issue":"1","key":"1054_CR129","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"C.V. Dang","year":"2012","unstructured":"C.V. Dang, MYC on the path to cancer. Cell. 149(1), 22\u201335 (2012). https:\/\/doi.org\/10.1016\/j.cell.2012.03.003","journal-title":"Cell"},{"issue":"4","key":"1054_CR130","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-07-1305","volume":"14","author":"K.K. Mantripragada","year":"2008","unstructured":"K.K. Mantripragada, G. Spurlock, L. Kluwe, N. Chuzhanova, R.E. Ferner, I.M. Frayling, J.P. Dumanski, A. Guha, V. Mautner, M. Upadhyaya, High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin. Cancer. Res. 14(4), 1015\u20131024 (2008). https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1305","journal-title":"Clin. Cancer. Res."},{"issue":"4","key":"1054_CR131","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/jnr.20648","volume":"82","author":"I. Dang","year":"2005","unstructured":"I. Dang, J.K. Nelson, G. H, DeVries. c-Kit receptor expression in normal human Schwann cells and Schwann cell lines derived from neurofibromatosis type 1 tumors. J. Neurosci. Res. 82(4), 465\u2013471 (2005). https:\/\/doi.org\/10.1002\/jnr.20648","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"1054_CR132","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-009-9862-z","volume":"94","author":"D. Keizman","year":"2009","unstructured":"D. Keizman, J. Issakov, I. Meller, N. Maimon, M. Ish-Shalom, O. Sher, O. Merimsky, Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J. Neurooncol. 94(3), 383\u2013388 (2009). https:\/\/doi.org\/10.1007\/s11060-009-9862-z","journal-title":"J. Neurooncol."},{"issue":"9","key":"1054_CR133","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1172\/JCI7610","volume":"105","author":"J.E. DeClue","year":"2000","unstructured":"J.E. DeClue, S. Heffelfinger, G. Benvenuto, B. Ling, S. Li, W. Rui, W.C. Vass, D. Viskochil, N. Ratner, Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J. Clin. Invest. 105(9), 1233\u20131241 (2000). https:\/\/doi.org\/10.1172\/JCI7610","journal-title":"J. Clin. Invest."},{"issue":"2","key":"1054_CR134","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/onc.2012.579","volume":"33","author":"J. Wu","year":"2014","unstructured":"J. Wu, D.M. Patmore, E. Jousma, D.W. Eaves, K. Breving, A.V. Patel, E.B. Schwartz, J.R. Fuchs, T.P. Cripe, A.O. Stemmer-Rachamimov, N. Ratner, EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 33(2), 173\u2013180 (2014). https:\/\/doi.org\/10.1038\/onc.2012.579","journal-title":"Oncogene"},{"issue":"3","key":"1054_CR135","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/carcin\/bgi273","volume":"27","author":"N. Holtkamp","year":"2006","unstructured":"N. Holtkamp, A.F. Okuducu, J. Mucha, A. Afanasieva, C. Hartmann, I. Atallah, L. Estevez-Schwarz, C. Mawrin, R.E. Friedrich, V.F. Mautner, A. von Deimling, Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 27(3), 664\u2013671 (2006). https:\/\/doi.org\/10.1093\/carcin\/bgi273","journal-title":"Carcinogenesis"},{"issue":"24","key":"1054_CR136","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1038\/s41388-021-01773-x","volume":"40","author":"C.S. Thomson","year":"2021","unstructured":"C.S. Thomson, J. Pundavela, M.R. Perrino, R.A. Coover, K. Choi, K.E. Chaney, T.A. Rizvi, D.A. Largaespada, N. Ratner, WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene. 40(24), 4229\u20134241 (2021). https:\/\/doi.org\/10.1038\/s41388-021-01773-x","journal-title":"Oncogene"},{"issue":"3","key":"1054_CR137","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/NEN.0b013e3182859939","volume":"72","author":"S.J. Byer","year":"2013","unstructured":"S.J. Byer, N.M. Brossier, L.T. Peavler, J.M. Eckert, S. Watkins, K.A. Roth, S.L. Carroll, Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands. J. Neuropathol. Exp. Neurol. 72(3), 219\u2013233 (2013). https:\/\/doi.org\/10.1097\/NEN.0b013e3182859939","journal-title":"J. Neuropathol. Exp. Neurol"},{"issue":"2","key":"1054_CR138","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/humu.10305","volume":"23","author":"M. Upadhyaya","year":"2004","unstructured":"M. Upadhyaya, S. Han, C. Consoli, E. Majounie, M. Horan, N.S. Thomas, C. Potts, S. Griffiths, M. Ruggieri, A. von Deimling, D.N. Cooper, Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum. Mutat. 23(2), 134\u2013146 (2004). https:\/\/doi.org\/10.1002\/humu.10305","journal-title":"Hum. Mutat."},{"issue":"6","key":"1054_CR139","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/SLA.0b013e3181a77e9a","volume":"249","author":"C. Zou","year":"2009","unstructured":"C. Zou, K.D. Smith, J. Liu, G. Lahat, S. Myers, W.L. Wang, W. Zhang, I.E. McCutcheon, J.M. Slopis, A.J. Lazar, R.E. Pollock, D. Lev, Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann. Surg. 249(6), 1014\u20131022 (2009). https:\/\/doi.org\/10.1097\/SLA.0b013e3181a77e9a","journal-title":"Ann. Surg"},{"issue":"3","key":"1054_CR140","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/neuonc\/not248","volume":"16","author":"A.C. Hirbe","year":"2014","unstructured":"A.C. Hirbe, M. Pekmezci, S. Dahiya, A.J. Apicelli, B.A. Van Tine, A. Perry, D.H. Gutmann, BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro. Oncol. 16(3), 466\u2013467 (2014). https:\/\/doi.org\/10.1093\/neuonc\/not248","journal-title":"Neuro. Oncol."},{"issue":"1","key":"1054_CR141","doi-asserted-by":"publisher","first-page":"14992","DOI":"10.1038\/s41598-017-15183-1","volume":"7","author":"A.S. Brohl","year":"2017","unstructured":"A.S. Brohl, E. Kahen, S.J. Yoder, J.K. Teer, D.R. Reed, The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci. Rep. 7(1), 14992 (2017). https:\/\/doi.org\/10.1038\/s41598-017-15183-1","journal-title":"Sci. Rep."},{"issue":"1","key":"1054_CR142","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-015-0288-2","volume":"14","author":"B. Ju","year":"2015","unstructured":"B. Ju, W. Chen, B.A. Orr, J.M. Spitsbergen, S. Jia, C.J. Eden, H.E. Henson, M.R. Taylor, Oncogenic KRAS promotes malignant brain tumors in zebrafish. Mol. Cancer. 14(1), 18 (2015). https:\/\/doi.org\/10.1186\/s12943-015-0288-2","journal-title":"Mol. Cancer"},{"issue":"24","key":"1054_CR143","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"C.M. Johannessen","year":"2005","unstructured":"C.M. Johannessen, E.E. Reczek, M.F. James, H. Brems, E. Legius, K. Cichowski, The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U. S. A. 102(24), 8573\u20138578 (2005). https:\/\/doi.org\/10.1073\/pnas.0503224102","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"1054_CR144","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","volume":"19","author":"M. Endo","year":"2013","unstructured":"M. Endo, H. Yamamoto, N. Setsu, K. Kohashi, Y. Takahashi, T. Ishii, K. Iida, Y. Matsumoto, M. Hakozaki, M. Aoki, H. Iwasaki, Y. Dobashi, K. Nishiyama, Y. Iwamoto, Y. Oda, Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer. Res. 19(2), 450\u2013461 (2013). https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1067","journal-title":"Clin. Cancer. Res."},{"issue":"7","key":"1054_CR145","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","volume":"65","author":"B. Dasgupta","year":"2005","unstructured":"B. Dasgupta, Y. Yi, D.Y. Chen, J.D. Weber, D.H. Gutmann, Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 65(7), 2755\u20132760 (2005). https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4058","journal-title":"Cancer Res"},{"issue":"24","key":"1054_CR146","doi-asserted-by":"publisher","first-page":"35753","DOI":"10.18632\/oncotarget.7099","volume":"7","author":"J. Varin","year":"2016","unstructured":"J. Varin, L. Poulain, M. Hivelin, P. Nusbaum, A. Hubas, I. Laurendeau, L. Lantieri, P. Wolkenstein, M. Vidaud, E. Pasmant, N. Chapuis, B. Parfait, Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget. 7(24), 35753\u201335767 (2016). https:\/\/doi.org\/10.18632\/oncotarget.7099","journal-title":"Oncotarget"},{"key":"1054_CR147","doi-asserted-by":"publisher","unstructured":"A. Schulte, F. Ewald, M. Spyra, D.J. Smit, W. Jiang, J. Salamon, M. Jucker, V.F. Mautner, Combined targeting of AKT and mTOR inhibits proliferation of human NF1-associated malignant peripheral nerve sheath tumour cells in vitro but not in a Xenograft mouse model in vivo. Int. J. Mol. Sci. 21(4), (2020). https:\/\/doi.org\/10.3390\/ijms21041548","DOI":"10.3390\/ijms21041548"},{"issue":"12","key":"1054_CR148","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/2326-6066.CIR-18-0014","volume":"6","author":"M.G. Ghonime","year":"2018","unstructured":"M.G. Ghonime, K.A. Cassady, Combination therapy using ruxolitinib and oncolytic HSV renders resistant MPNSTs susceptible to virotherapy. Cancer Immunol. Res. 6(12), 1499\u20131510 (2018). https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0014","journal-title":"Cancer Immunol. Res"},{"issue":"2","key":"1054_CR149","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ccell.2018.01.005","volume":"33","author":"L.M.N. Wu","year":"2018","unstructured":"L.M.N. Wu, Y. Deng, J. Wang, C. Zhao, J. Wang, R. Rao, L. Xu, W. Zhou, K. Choi, T.A. Rizvi, M. Remke, J.B. Rubin, R.L. Johnson, T.J. Carroll, A.O. Stemmer-Rachamimov, J. Wu, Y. Zheng, M. Xin, N. Ratner, Q.R. Lu, Programming of Schwann Cells by Lats1\/2-TAZ\/YAP signaling drives malignant Peripheral Nerve Sheath Tumorigenesis. Cancer Cell. 33(2), 292\u2013308e297 (2018). https:\/\/doi.org\/10.1016\/j.ccell.2018.01.005","journal-title":"Cancer Cell"},{"issue":"1","key":"1054_CR150","doi-asserted-by":"publisher","first-page":"19704","DOI":"10.1038\/s41598-019-56247-8","volume":"9","author":"I. Isfort","year":"2019","unstructured":"I. Isfort, S. Elges, M. Cyra, R. Berthold, M. Renner, G. Mechtersheimer, P. Aman, O. Larsson, N. Ratner, S. Hafner, T. Simmet, C. Schliemann, C. Rossig, U. Dirksen, I. Grunewald, E. Wardelmann, S. Huss, W. Hartmann, M. Trautmann, Prevalence of the Hippo Effectors YAP1\/TAZ in tumors of soft tissue and bone. Sci. Rep. 9(1), 19704 (2019). https:\/\/doi.org\/10.1038\/s41598-019-56247-8","journal-title":"Sci. Rep."},{"key":"1054_CR151","doi-asserted-by":"publisher","unstructured":"G.L. Velez-Reyes, N. Koes, J.H. Ryu, G. Kaufmann, M. Berner, M.T. Weg, N.K. Wolf, S.K. Rathe, N. Ratner, B.S. Moriarity, D.A. Largaespada, Transposon mutagenesis-guided CRISPR\/Cas9 screening strongly implicates dysregulation of Hippo\/YAP signaling in malignant peripheral nerve sheath tumor development. Cancers (Basel). 13(7), (2021). https:\/\/doi.org\/10.3390\/cancers13071584","DOI":"10.3390\/cancers13071584"},{"issue":"2","key":"1054_CR152","first-page":"873","volume":"12","author":"P.Y. Huang","year":"2022","unstructured":"P.Y. Huang, I.A. Shih, Y.C. Liao, H.L. You, M.J. Lee, A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway. Am. J. Cancer Res. 12(2), 873\u2013892 (2022)","journal-title":"Am. J. Cancer Res"},{"key":"1054_CR200","doi-asserted-by":"crossref","unstructured":"W. Mo et al., CXCR4\/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 152(5), 1077\u201390 (2013). PMID: 23434321","DOI":"10.1016\/j.cell.2013.01.053"},{"issue":"6","key":"1054_CR153","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0081","volume":"3","author":"A.L. Watson","year":"2013","unstructured":"A.L. Watson, E.P. Rahrmann, B.S. Moriarity, K. Choi, C.B. Conboy, A.D. Greeley, A.L. Halfond, L.K. Anderson, B.R. Wahl, V.W. Keng, A.E. Rizzardi, C.L. Forster, M.H. Collins, A.L. Sarver, M.R. Wallace, S.C. Schmechel, N. Ratner, D.A. Largaespada, Canonical Wnt\/beta-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 3(6), 674\u2013689 (2013). https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0081","journal-title":"Cancer Discov"},{"issue":"38","key":"1054_CR154","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/onc.2017.143","volume":"36","author":"G. Semenova","year":"2017","unstructured":"G. Semenova, D.S. Stepanova, C. Dubyk, E. Handorf, S.M. Deyev, A.J. Lazar, J. Chernoff, Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. 36(38), 5421\u20135431 (2017). https:\/\/doi.org\/10.1038\/onc.2017.143","journal-title":"Oncogene"},{"issue":"1","key":"1054_CR155","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1038\/s41467-023-38432-6","volume":"14","author":"S. Suppiah","year":"2023","unstructured":"S. Suppiah, S. Mansouri, Y. Mamatjan, J.C. Liu, M.M. Bhunia, V. Patil, P. Rath, B. Mehani, P. Heir, S. Bunda, G.L. Velez-Reyes, O. Singh, N. Ijad, N. Pirouzmand, T. Dalcourt, Y. Meng, S. Karimi, Q. Wei, F. Nassiri, T.J. Pugh, G.D. Bader, K.D. Aldape, D.A. Largaespada, G. Zadeh, Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. Nat. Commun. 14(1), 2696 (2023). https:\/\/doi.org\/10.1038\/s41467-023-38432-6","journal-title":"Nat. Commun."},{"issue":"6","key":"1054_CR156","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1215\/15228517-2008-053","volume":"10","author":"N. Holtkamp","year":"2008","unstructured":"N. Holtkamp, E. Malzer, J. Zietsch, A.F. Okuducu, J. Mucha, C. Mawrin, V.F. Mautner, H.U. Schildhaus, A. von Deimling, EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro. Oncol. 10(6), 946\u2013957 (2008). https:\/\/doi.org\/10.1215\/15228517-2008-053","journal-title":"Neuro. Oncol."},{"key":"1054_CR157","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/1471-2407-13-224","volume":"13","author":"J. Ohishi","year":"2013","unstructured":"J. Ohishi, M. Aoki, K. Nabeshima, J. Suzumiya, T. Takeuchi, A. Ogose, M. Hakozaki, Y. Yamashita, H. Iwasaki, Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-beta. BMC Cancer. 13, 224 (2013). https:\/\/doi.org\/10.1186\/1471-2407-13-224","journal-title":"BMC Cancer"},{"issue":"8","key":"1054_CR158","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/labinvest.3700591","volume":"87","author":"M. Aoki","year":"2007","unstructured":"M. Aoki, K. Nabeshima, K. Koga, M. Hamasaki, J. Suzumiya, K. Tamura, H. Iwasaki, Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab. Invest. 87(8), 767\u2013779 (2007). https:\/\/doi.org\/10.1038\/labinvest.3700591","journal-title":"Lab. Invest."},{"issue":"6","key":"1054_CR159","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/cncr.29858","volume":"122","author":"S.M. Schuetze","year":"2016","unstructured":"S.M. Schuetze, J.K. Wathen, D.R. Lucas, E. Choy, B.L. Samuels, A.P. Staddon, K.N. Ganjoo, M. von Mehren, W.A. Chow, D.M. Loeb, H.A. Tawbi, D.A. Rushing, S.R. Patel, D.G. Thomas, R. Chugh, D.K. Reinke, L.H. Baker, SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 122(6), 868\u2013874 (2016). https:\/\/doi.org\/10.1002\/cncr.29858","journal-title":"Cancer"},{"key":"1054_CR160","doi-asserted-by":"publisher","first-page":"7656747","DOI":"10.1155\/2019\/7656747","volume":"2019","author":"B.C. Widemann","year":"2019","unstructured":"B.C. Widemann, Y. Lu, D. Reinke, S.H. Okuno, C.F. Meyer, G.M. Cote, R. Chugh, M.M. Milhem, A.C. Hirbe, A. Kim, B. Turpin, J.G. Pressey, E. Dombi, N. Jayaprakash, L.J. Helman, N. Onwudiwe, K. Cichowski, J.P. Perentesis, Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019, 7656747 (2019). https:\/\/doi.org\/10.1155\/2019\/7656747","journal-title":"Sarcoma"},{"issue":"4","key":"1054_CR161","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B. Weiss","year":"2015","unstructured":"B. Weiss, B.C. Widemann, P. Wolters, E. Dombi, A. Vinks, A. Cantor, J. Perentesis, E. Schorry, N. Ullrich, D.H. Gutmann, J. Tonsgard, D. Viskochil, B. Korf, R.J. Packer, M.J. Fisher, Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study. Neuro. Oncol. 17(4), 596\u2013603 (2015). https:\/\/doi.org\/10.1093\/neuonc\/nou235","journal-title":"Neuro. Oncol."},{"issue":"5","key":"1054_CR162","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","volume":"7","author":"G. Johansson","year":"2008","unstructured":"G. Johansson, Y.Y. Mahller, M.H. Collins, M.O. Kim, T. Nobukuni, J. Perentesis, T.P. Cripe, H.A. Lane, S.C. Kozma, G. Thomas, N. Ratner, Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 7(5), 1237\u20131245 (2008). https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-2335","journal-title":"Mol. Cancer Ther"},{"issue":"1","key":"1054_CR163","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41698-021-00145-8","volume":"5","author":"S. Nagabushan","year":"2021","unstructured":"S. Nagabushan, L.M.S. Lau, P. Barahona, M. Wong, A. Sherstyuk, G.M. Marshall, V. Tyrrell, E.A. Wegner, P.G. Ekert, M.J. Cowley, C. Mayoh, T.N. Trahair, P. Crowe, A. Anazodo, D.S. Ziegler, Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor. NPJ Precis. Oncol. 5(1), 9 (2021). https:\/\/doi.org\/10.1038\/s41698-021-00145-8","journal-title":"NPJ Precis. Oncol"},{"issue":"12","key":"1054_CR164","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.5858\/2006-130-1878-MPNSTW","volume":"130","author":"C.J. Stasik","year":"2006","unstructured":"C.J. Stasik, O. Tawfik, Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch. Pathol. Lab. Med. 130(12), 1878\u20131881 (2006). https:\/\/doi.org\/10.5858\/2006-130-1878-MPNSTW","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"1054_CR165","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejso.2012.09.001","volume":"39","author":"S.C. Kamran","year":"2013","unstructured":"S.C. Kamran, S.A. Howard, A.B. Shinagare, K.M. Krajewski, J.P. Jagannathan, J.L. Hornick, N.H. Ramaiya, Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. Eur. J. Surg. Oncol. 39(1), 46\u201352 (2013). https:\/\/doi.org\/10.1016\/j.ejso.2012.09.001","journal-title":"Eur. J. Surg. Oncol"},{"key":"1054_CR166","doi-asserted-by":"publisher","first-page":"203636132095086","DOI":"10.1177\/2036361320950862","volume":"12","author":"N. Heatley","year":"2020","unstructured":"N. Heatley, E. Kolson Kokohaare, D.C. Strauss, M. Hallin, R.L. Jones, C. Fisher, K. Thway, Epithelioid malignant peripheral nerve sheath tumor arising in schwannoma. Rare Tumors. 12, 2036361320950862 (2020). https:\/\/doi.org\/10.1177\/2036361320950862","journal-title":"Rare Tumors"},{"issue":"5","key":"1054_CR167","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/PAS.0000000000000379","volume":"39","author":"V.Y. Jo","year":"2015","unstructured":"V.Y. Jo, C.D. Fletcher, Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases. Am. J. Surg. Pathol. 39(5), 673\u2013682 (2015). https:\/\/doi.org\/10.1097\/PAS.0000000000000379","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"1054_CR168","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/his.12756","volume":"68","author":"B. Luzar","year":"2016","unstructured":"B. Luzar, R. Shanesmith, R. Ramakrishnan, C. Fisher, E. Calonje, Cutaneous epithelioid malignant peripheral nerve sheath tumour: a clinicopathological analysis of 11 cases. Histopathology. 68(2), 286\u2013296 (2016). https:\/\/doi.org\/10.1111\/his.12756","journal-title":"Histopathology"},{"issue":"6","key":"1054_CR169","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00428-021-03218-y","volume":"480","author":"K. Yamashita","year":"2022","unstructured":"K. Yamashita, Y. Funauchi, K. Hayakawa, K. Ae, S. Matsumoto, K. Ikuta, Y. Nishida, T. Ueno, Y. Shimoyama, N. Hiruta, R. Machinami, H. Kawachi, K. Takeuchi, S100-negative epithelioid malignant peripheral nerve sheath tumor with possible perineurial differentiation. Virchows Arch. 480(6), 1269\u20131275 (2022). https:\/\/doi.org\/10.1007\/s00428-021-03218-y","journal-title":"Virchows Arch."},{"issue":"4","key":"1054_CR170","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/PAS.0000000000000564","volume":"40","author":"C.N. Prieto-Granada","year":"2016","unstructured":"C.N. Prieto-Granada, T. Wiesner, J.L. Messina, A.A. Jungbluth, P. Chi, C.R. Antonescu, Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am. J. Surg. Pathol. 40(4), 479\u2013489 (2016). https:\/\/doi.org\/10.1097\/PAS.0000000000000564","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"1054_CR171","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-024-01767-7","volume":"9","author":"R. Hosea","year":"2024","unstructured":"R. Hosea, S. Hillary, S. Naqvi, S. Wu, V. Kasim, The two sides of chromosomal instability: drivers and brakes in cancer. Signal Transduct. Target Ther. 9(1), 75 (2024). https:\/\/doi.org\/10.1038\/s41392-024-01767-7","journal-title":"Signal Transduct. Target Ther"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01054-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:05:29Z","timestamp":1752138329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-025-01054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s13402-025-01054-9","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The immunohistochemistry staining of tumor sections was approved by the institutional review board of Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine (SH9H-2019-T163-2, SH9H-2019-T163-5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Author Z.W. is an associate editor of Cellular Oncology. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}